Clinical Trial Update: Study to Investigate the Long-term Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating the long-term safety of FAB122 in amyotrophic lateral sclerosis was terminated, and the results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• FAB122

Snippet

Sponsor: Ferrer Internacional S.A. | Conditions: Amyotrophic Lateral Sclerosis | Phase 3 | Status: TERMINATED | Results posted: 2025-03-04